AKBA Inks Blockbuster Deal, AGN On Buying Spree, TSRO Gets FDA Date

TESARO Inc.'s (TSRO) New Drug Application seeking approval of Niraparib as a potential new treatment option for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer following response to platinum-based chemotherapy, has been granted Priority Review by the FDA - with a decision date set for June 30, 2017.

from RTT - Biotech http://ift.tt/2h8wEPT
via IFTTT